Anteris Technologies Global (NASDAQ:AVR) Issues Quarterly Earnings Results

Anteris Technologies Global (NASDAQ:AVR) posted its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03, FiscalAI reports. Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $2.75 million.

Anteris Technologies Global Stock Up 2.5%

Shares of NASDAQ:AVR traded up $0.15 during trading on Wednesday, hitting $6.04. 158,001 shares of the stock traded hands, compared to its average volume of 1,156,362. The company has a market cap of $588.66 million, a price-to-earnings ratio of -3.10 and a beta of 2.02. The company has a fifty day moving average price of $7.13 and a two-hundred day moving average price of $7.39. Anteris Technologies Global has a 52-week low of $3.30 and a 52-week high of $11.06.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Barclays raised shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Wednesday, October 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

Insider Activity

In other news, major shareholder L1 Capital Pty Ltd purchased 648,455 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were purchased at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the completion of the acquisition, the insider owned 12,778,380 shares of the company’s stock, valued at approximately $95,965,633.80. This represents a 5.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have acquired 1,554,730 shares of company stock valued at $11,694,513. Insiders own 4.50% of the company’s stock.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.